Paragard IUD Lawsuit Settlement Amounts 2026

Paragard Settlement Amount Tiers — February 2026

Paragard IUD settlement projections are estimated based on the injury severity framework developed by plaintiffs' counsel in MDL 2974, comparable medical device mass tort outcomes (Essure, Mirena, Bard PowerPort), and the bellwether trial process. As of February 2026, no global MDL settlement has been reached. The February 5, 2026 Teva defense verdict in the first bellwether trial (Rickard v. Teva) has introduced uncertainty into projections, but the litigation continues with two more bellwether trials scheduled. The settlement tier framework reflects four injury levels, from minor surgical intervention to catastrophic infertility.

Tier 1 — Infertility and Catastrophic Injury ($100K–$380K)

The highest settlement tier in Paragard litigation is reserved for women who suffered confirmed infertility, hysterectomy, or catastrophic organ injury directly caused by Paragard IUD breakage. Women in this tier typically: are younger (under 35) with a documented desire for future children; required hysterectomy, major laparotomy, or multiple surgeries; suffered permanent loss of reproductive capacity; and have strong medical documentation tracing the causal chain from device fracture to infertility. Settlement projections of $100,000 to $380,000 reflect outcomes from comparable medical device mass torts and the reproductive loss damages available in these cases. Outlier jury verdicts — such as the $2.1 million verdict in Chen v. CooperSurgical (New York, 2025) — demonstrate that individual cases with exceptional facts can exceed tier projections significantly.

Tier 2 — Hysterectomy or Major Organ Damage ($100K–$200K)

Tier 2 includes women who required hysterectomy or suffered major organ damage without confirmed infertility as the primary damages theory — for example, older women who had completed their families but who underwent hysterectomy, bowel surgery, or bladder repair due to Paragard migration. The major surgical intervention and recovery period, combined with the permanent nature of hysterectomy and organ damage, justify settlement projections in the $100,000 to $200,000 range. Economic damages in these cases are significant: operative costs, anesthesia, hospitalization, and extended recovery affecting employment.

Tier 3 — Significant Surgery, No Permanent Loss ($50K–$100K)

Tier 3 encompasses women who required laparoscopy or complex hysteroscopy with documented complications — uterine perforation, pelvic inflammatory disease, or significant scarring — but who achieved full or substantial recovery without permanent organ loss. Settlement projections of $50,000 to $100,000 reflect the surgical costs, recovery period, and non-economic pain and suffering damages, while acknowledging the absence of permanent reproductive injury.

Tier 4 — Minor Intervention, No Lasting Injury ($10K–$50K)

The lowest tier includes cases where a Paragard arm broke during removal and was retrieved via straightforward hysteroscopy, with complete recovery and no lasting fertility impact or organ damage. These cases have settlement projections of $10,000 to $50,000, reflecting the cost of the additional surgical procedure and associated pain and inconvenience, but limited long-term damages. Cases in this tier remain compensable but are less priority for litigation funding allocation than higher-tier cases.

How the Teva Defense Verdict Affects Settlement Projections

The February 5, 2026 defense verdict in Rickard v. Teva introduces downward pressure on Tier 4 and Tier 3 cases — particularly those where the primary theory is failure-to-warn and the injury is limited to a fragment retrieval without serious surgical complications. Teva's defense argument — that the label adequately disclosed the arm fracture risk — was accepted by that jury, and defendants will invoke the verdict in settlement negotiations to push compensation lower. However, cases with stronger fact patterns are distinguishable: infertility, hysterectomy, and major organ damage cases have damages so significant that Teva's litigation risk remains substantial regardless of the Rickard outcome. The March and May 2026 bellwether trials will provide additional data points that further refine settlement positioning for all tiers.